In the BioHarmony Drug Report Database
Ridaura (auranofin) is a small molecule pharmaceutical. Auranofin was first approved as Ridaura on 1985-05-24. It is used to treat pemphigus, psoriatic arthritis, and rheumatoid arthritis in the USA. It is known to target transient receptor potential cation channel subfamily A member 1.
Image (chem structure or protein)